Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340

Showing 26-50 of 340 citing articles:

Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 78
Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms
Caroline Atyeo, Lydia L. Shook, Sara Brigida, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 75
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
Youyi Fong, Adrian B. McDermott, David Benkeser, et al.
Nature Microbiology (2022) Vol. 7, Iss. 12, pp. 1996-2010
Open Access | Times Cited: 73
Predicting the efficacy of variant-modified COVID-19 vaccine boosters
David S. Khoury, Steffen S. Docken, Kanta Subbarao, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 574-578
Open Access | Times Cited: 73
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 72
Viral vector vaccines
Naina McCann, Daniel O’Connor, Teresa Lambe, et al.
Current Opinion in Immunology (2022) Vol. 77, pp. 102210-102210
Open Access | Times Cited: 70
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
Shô Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
Med (2022) Vol. 3, Iss. 4, pp. 249-261.e4
Open Access | Times Cited: 69
Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections
Nina Breinholt Stærke, Joanne Reekie, Henrik Nielsen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 69
Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K. Hayden, Ibrahim K El Mikati, Kimberly E. Hanson, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 61
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Lihong Liu, Sho Iketani, Yicheng Guo, et al.
Nature (2021)
Closed Access | Times Cited: 83
The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines
Bruna Aparecida Souza Machado, Katharine Valéria Saraiva Hodel, Larissa Moraes dos Santos Fonseca, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 591-591
Open Access | Times Cited: 62
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
Weihao Shao, Xiaorui Chen, Caifang Zheng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 2383-2392
Open Access | Times Cited: 62
mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern
Rishi R. Goel, Mark M. Painter, Sokratis A. Apostolidis, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 61
SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Ranjan K. Mohapatra, Satwik Kuppili, Tarun Kumar Suvvari, et al.
Chemical Biology & Drug Design (2022) Vol. 99, Iss. 5, pp. 769-788
Open Access | Times Cited: 58
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months
Guruprasad R. Medigeshi, Gaurav Batra, Deepika Rathna Murugesan, et al.
EBioMedicine (2022) Vol. 78, pp. 103938-103938
Open Access | Times Cited: 54
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records
Elsie Horne, William Hulme, Ruth H. Keogh, et al.
BMJ (2022), pp. e071249-e071249
Open Access | Times Cited: 54
A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines
Joey Ming Er Lim, Shou Kit Hang, Smrithi Hariharaputran, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100793-100793
Open Access | Times Cited: 54
The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants
Marios Koutsakos, Wen Shi Lee, Arnold Reynaldi, et al.
Immunity (2022) Vol. 55, Iss. 7, pp. 1316-1326.e4
Open Access | Times Cited: 53
Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era
Rosanna C. Barnard, Nicholas G. Davies, James D. Munday, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 50
Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 45
Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses
Harikrishnan Balachandran, Chansavath Phetsouphanh, David Agapiou, et al.
Cell Reports (2022) Vol. 38, Iss. 6, pp. 110345-110345
Open Access | Times Cited: 44
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia
Anupriya Aggarwal, Alberto Ospina Stella, Gregory J. Walker, et al.
Nature Microbiology (2022) Vol. 7, Iss. 6, pp. 896-908
Open Access | Times Cited: 43
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
Li Wang, Markus H. Kainulainen, Nannan Jiang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43
Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021
Shirley L. L. Kwok, Samuel M. S. Cheng, Jennifer NS Leung, et al.
Eurosurveillance (2022) Vol. 27, Iss. 2
Open Access | Times Cited: 42
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42

Scroll to top